For help on how to get the results you want, see our search tips.
1721 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Ondexxya (updated)
andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019,
, 
, Revision: 15, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Jyseleca (updated)
filgotinib maleate, Arthritis, Rheumatoid
Date of authorisation: 24/09/2020,
, , Revision: 9, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Zolgensma (updated)
onasemnogene abeparvovec, Muscular Atrophy, Spinal
Date of authorisation: 18/05/2020,, 
, , Revision: 11, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Rivaroxaban Mylan (updated)
rivaroxaban, Venous Thromboembolism; Pulmonary Embolism; Acute Coronary Syndrome; Stroke; Coronary Artery Disease; Peripheral Arterial Disease; Atrial Fibrillation
Date of authorisation: 12/11/2021,
, Revision: 3, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Pombiliti (updated)
Cipaglucosidase alfa, Glycogen Storage Disease Type II
Date of authorisation: 20/03/2023,, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Qinlock (updated)
ripretinib, Gastrointestinal Stromal Tumors
Date of authorisation: 18/11/2021,, , Revision: 3, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Ratiograstim (updated)
filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 15/09/2008,
, Revision: 16, Authorised, Last updated: 30/05/2023
-
List item
Human medicine European public assessment report (EPAR): Vokanamet (updated)
canagliflozin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 23/04/2014, Revision: 21, Authorised, Last updated: 30/05/2023 -
List item
Human medicine European public assessment report (EPAR): Cinqaero (updated)
Reslizumab, Asthma
Date of authorisation: 15/08/2016, Revision: 11, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Procysbi (updated)
mercaptamine bitartrate, Cystinosis
Date of authorisation: 05/09/2013,, Revision: 16, Authorised, Last updated: 26/05/2023
-
List item
Human medicine European public assessment report (EPAR): Ogluo (updated)
Glucagon, Diabetes Mellitus
Date of authorisation: 11/02/2021, Revision: 5, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Lyrica (updated)
pregabalin, Epilepsy; Anxiety Disorders; Neuralgia
Date of authorisation: 05/07/2004, Revision: 60, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Beovu (updated)
brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020,, Revision: 8, Authorised, Last updated: 26/05/2023
-
List item
Human medicine European public assessment report (EPAR): Ixiaro (updated)
Japanese-encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells), Encephalitis, Japanese; Immunization
Date of authorisation: 31/03/2009, Revision: 17, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Breyanzi (updated)
CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells), CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells), Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms
Date of authorisation: 04/04/2022,, Revision: 1, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Livmarli (updated)
Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022,, , 
, Revision: 1, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Galafold (updated)
Migalastat hydrochloride, Fabry Disease
Date of authorisation: 25/05/2016,, , Revision: 16, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories) (updated)
6-mercaptopurine monohydrate, Leukemia, Lymphoid
Date of authorisation: 09/03/2012, Revision: 15, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Sustiva (updated)
efavirenz, HIV Infections
Date of authorisation: 28/05/1999, Revision: 48, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Dupixent (updated)
dupilumab, Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis
Date of authorisation: 26/09/2017, Revision: 26, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Pantozol Control (updated)
pantoprazole, Gastroesophageal Reflux
Date of authorisation: 11/06/2009, Revision: 17, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Olumiant (updated)
Baricitinib, Arthritis, Rheumatoid
Date of authorisation: 13/02/2017,, Revision: 13, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Lixiana (updated)
edoxaban tosilate, Stroke; Venous Thromboembolism
Date of authorisation: 19/06/2015, Revision: 16, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Elfabrio (updated)
Pegunigalsidase alfa, Fabry Disease
Date of authorisation: 04/05/2023, Revision: 1, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Tenkasi (previously Orbactiv) (updated)
oritavancin diphosphate, Soft Tissue Infections; Skin Diseases, Bacterial
Date of authorisation: 19/03/2015, Revision: 12, Authorised, Last updated: 25/05/2023